Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...